pentadecapeptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-11-15 and is reviewed periodically as new material appears.
Laboratory research on this peptide has examined a wide and heterogeneous set of endpoints, including gastric ulcer models, tendon and ligament injury, wound closure, and intestinal inflammation. Most published findings come from rodent studies, and reported effect sizes are often large relative to controls. Because the compound has been tested across many unrelated injury models, the literature is frequently described as unusually broad for a single peptide. A substantial share of this work originates from a small number of research groups, which matters when assessing how widely results have been reproduced.
Evidence in humans is limited. Small clinical studies have examined the peptide in contexts such as ulcerative colitis and wound healing, but participant numbers are small and independent replication is scarce. It is not approved as a medicine by major regulatory agencies and is distributed mainly as a research material or compounded preparation. Long-term human safety data are not established, and questions about absorption through non-injected routes remain open rather than resolved. Claims about its effects are best read against these gaps.
BPC-157 is a synthetic peptide of fifteen amino acids, written in single-letter code as GEPPPGKPADDAGLV. The sequence corresponds to a partial fragment of a protein isolated from human gastric juice, described in early reports as body protection compound. The number 157 refers to a fragment designation in that work rather than to molecular mass. Initial descriptions appeared in the early 1990s, when the fragment was reported to protect gastrointestinal tissue in animal models. Commercial material is produced by solid-phase peptide synthesis rather than extracted from biological sources.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated sequences and other synthesis by-products. Mass spectrometry, typically electrospray ionization coupled to liquid chromatography, confirms the expected mass and helps detect modifications. Amino acid analysis can verify composition when residue-level confirmation is needed. Because common impurities differ from the target by only one or two residues, chromatographic resolution often matters more than a single headline purity percentage. Impurity profiles are most informative when compared against a validated reference standard.
Lyophilized material is generally reported as stable for extended periods when kept cold, dry, and protected from light. In solution, the main degradation routes for a peptide of this type are hydrolysis of peptide bonds and aggregation. The sequence contains no cysteine, so disulfide-driven oxidation is not a primary concern, though methionine and tryptophan are also absent. Stability depends on pH, buffer composition, and concentration, with acidic conditions often reported as more favorable than neutral or alkaline ones. Repeated freeze-thaw cycles can promote aggregation, and how fast degradation proceeds at room temperature in specific formulations remains an open question.
Handling practice centers on limiting moisture, heat, and mechanical stress. Powder is typically allowed to reach room temperature before opening so that condensation does not form on the contents, and solutions are prepared with sterile or low-particulate water. Peptides can adsorb to certain plastics and membrane filters, so container and filter material is sometimes specified to reduce losses at low concentrations. Working aliquots are usually frozen separately rather than sampled repeatedly from one stock. Recording lot number, preparation date, and storage conditions supports later comparison between experiments.
| Property | Value | Notes |
|---|---|---|
| Class | Synthetic peptide | Linear, fifteen residues |
| Sequence | GEPPPGKPADDAGLV | Single-letter amino acid code |
| Approximate mass | 1419 Da | Value reported for the free peptide |
| Reported origin | Fragment of a gastric juice protein | Used as the design template |
| Common synonyms | Body protection compound 157; PL 14736 | Naming varies across papers and suppliers |
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
BPC-157 is a synthetic pentadecapeptide with the sequence GEPPPGKPADDAGLV, corresponding to a partial fragment of a larger protein detected in human gastric juice. The name derives from the parent protein designation BPC, an abbreviation of body protection compound, with 157 acting as a fraction or batch identifier used by the original investigators. Its molecular weight is approximately 1419 daltons, and the chain contains no unusual residues or disulfide bridges. In the literature it is described as a short, water-soluble fragment rather than a complete natural protein.
Analytical results depend on the column, gradient, and detector wavelength chosen by the laboratory, so purity values from different sources are not always directly comparable. Water content, counterion form, and residual trifluoroacetate affect both mass and purity calculations. Microbiological and endotoxin testing are separate from chemical purity and are not covered by a standard chromatographic run. Buyers evaluating a material typically request the full method description rather than a single purity figure.
Lyophilized peptide powder is generally stored at minus twenty degrees Celsius or lower and kept away from light and moisture. Under these conditions degradation is slow, and sealed vials remain stable for extended periods. Once dissolved, the material is less stable, particularly in aqueous buffers near neutral pH, where hydrolysis and oxidation proceed faster. Solutions are usually kept cold and used within days to weeks. Repeated freeze-thaw cycles are avoided because they encourage aggregation.
Identity and purity are established using reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities and yields a percentage purity. Mass spectrometry, typically with electrospray ionization, confirms the molecular mass against the expected value. Amino acid analysis or peptide mapping provides additional sequence confirmation. These methods are complementary, since chromatography measures how much material is present while mass spectrometry verifies what that material is. A certificate of analysis normally reports both.
Identity and purity are established with complementary methods rather than one test. Reverse-phase high-performance liquid chromatography separates the main peak from deletion sequences and oxidized variants, and its area percentage is the usual purity figure. Mass spectrometry confirms the expected molecular mass and can flag truncations or modifications that chromatography alone might miss. Amino acid analysis and peptide mapping add sequence-level confirmation, while residual counter-ion and water content are measured separately.
A freeze-dried sample is generally the most stable form and is commonly held at minus twenty degrees Celsius or lower for long-term keeping, with brief transfers at room temperature. The solid is hygroscopic, so vials are warmed to ambient temperature before opening to prevent condensation from degrading the contents. Light exposure and repeated temperature cycling are both avoided in routine handling. Storage over a desiccant is a common laboratory practice that limits moisture uptake during repeated access.
=== Elimination of gingival enlargement === In cases of gingival enlargement induced by drugs, surgical treatment through a gingivectomy proved to be effective with most patients showing no clinical sign of recurrence after one year. Even though it is the most frequent method of treatment, it is only indicated when overgrowth is severe. Another cause of gingival enlargement would be a hereditary condition known as gingival fibromatosis. The extensive overgrowth of gingival tissue is usually treated with a gingivectomy, as it produces good aesthetic results. However, recurrence in these cases are unpredictable. This means that those affected face the possibility of undergoing repeated procedures.
3D food printing is the process of manufacturing food products using a variety of additive manufacturing techniques. Most commonly, food grade syringes hold the printing material, which is then deposited through a food grade nozzle layer by layer. The most advanced 3D food printers have pre-loaded recipes on board and also allow the user to remotely design their food on their computers, phones or some IoT device. The food can be customized in shape, color, texture, flavor or nutrition, which makes it very useful in various fields such as space exploration and healthcare.
Free fatty acid receptor 3 (FFAR3, also termed GPR41) protein is a G protein coupled receptor (i.e., GPR or GPCR) that in humans is encoded by the FFAR3 gene (i.e., GPR41 gene). GPRs reside on cell surfaces, bind specific signaling molecules, and thereby are activated to trigger certain functional responses in their parent cells. FFAR3 is a member of the free fatty acid receptor group of GPRs that includes FFAR1 (i.e., GPR40), FFAR2 (i.e., GPR43), and FFAR4 (i.e., GPR120). All of these FFARs are activated by fatty acids. FFAR3 and FFAR2 are activated by certain short-chain fatty acids (SC-FAs), i.e., fatty acids consisting of 2 to 6 carbon atoms whereas FFFAR1 and FFAR4 are activated by certain fatty acids that are 6 to more than 21 carbon atoms long. Hydroxycarboxylic acid receptor 2 is also activated by a SC-FA that activate FFAR3, i.e., butyric acid.
Sources: en.wikipedia.org
=== δ-scales with two anchoring reference materials === Measuring isotopic ratios by mass spectrometry includes multiple steps in which samples can undergo cross-contamination, including during sample preparation, leakage of gas through instrument valves, the generic category of phenomena called 'memory effects', and the introduction of blanks (foreign analyte measured as part of the sample). As a result of these instrument-specific effects the range in measured δ values can be lower than the true range in the original samples. To correct for such scale compression researchers calculate a "stretching factor" by measuring two isotopic reference materials (Coplen, 1988). For the hydrogen system the two reference materials are commonly VSMOW2 and SLAP2, where δ2HVSMOW2 = 0 and δ2HSLAP2 = -427.5 vs. VSMOW. If the measured difference between the two references is less than 427.5‰, all measured 2H/1H ratios are multiplied by the stretching factor required to bring the difference between the two reference materials in line with expectations. After this scaling, a factor is added to all measured isotopic ratios so that the reference materials attain their defined isotopic values. The carbon system also uses two anchoring reference materials (Coplen et al., 2006a; 2006b).
== Adverse effects == Side effects that are most often seen with this medication include dizziness, hypotension, headache. A clinical trial done on over 7000 participants showed higher rates of nasopharyngitis in those taking valsartan/hydrochlorothiazide (2.4% versus 1.9% in placebo). A dose-related side effect seen is hypotension, occurring in 0.7% of participants on the highest dose of the medication. Risk of hypotension and hyperkalemia increases when valsartan/hydrochlorothiazide is used with ACE inhibitors or aliskiren. Less common side effects that occur less than 1% of the time include angina pectoris, rash, syncope, abdominal pain, and vertigo.
=== September === 1 September – Education Secretary Jenny Gilruth confirms that Reinforced autoclaved aerated concrete (RAAC) has been found in 35 of Scotland's council-run schools after the roof of privately run Queen Victoria School in Dunblane had to be secured. The announcement follows revelations about the discovery of the concrete in schools in England, where more than 100 have been told to close affected buildings while repair work is carried out. 3 September – Neil Gray, Scotland's Wellbeing and Economy Secretary, says there is no immediate risk to schools in Scotland from defective concrete. 4 September – Connor Gibson is sentenced to life imprisonment with a minimum of 22 years for the sexual assault and murder of his sister, Amber Gibson, in November 2021. 5 September – First Minister Humza Yousaf outlines the programme for government legislation for the year ahead, including improvements to childcare, an extra £1bn for social security and pay improvements for social care staff. There are also plans to ban disposable vapes over environmental concerns. Former SNP MP Natalie McGarry is ordered to pay £66 for embezzling £25,000 from the SNP and a pro-independence group. 6 September – Nicola Sturgeon makes her first speech in the Scottish Parliament following her arrest in June. 7 September – Network Rail admits responsibility for a series of failings that led to the deaths of three people as a result of the Stonehaven derailment in August 2020. 8 September – Network Rail is fined £6.7m after admitting a series of failings that led to the Stonehaven train crash.
The results showed that the model could be applied to MLC, but better predictive behavior was found with concentrations of surfactant below the CMC, sub-micellar. A final type of model based on molecular properties of a solute is a branch of quantitative structure-activity relationships (QSAR). QSAR studies attempt to correlate biological activity of drugs, or a class of drugs, with structures. The normally accepted means of uptake for a drug, or its metabolite, is through partitioning into lipid bilayers. The descriptor most often used in QSAR to determine the hydrophobicity of a compound is the octanol-water partition coefficient, log P. MLC provides an attractive and practical alternative to QSAR. When micelles are added to a mobile phase, many similarities exist between the micellar mobile phase/stationary phase and the biological membrane/water interface. In MLC, the stationary phase become modified by the adsorption of surfactant monomers which are structurally similar to the membranous hydrocarbon chains in the biological model. Additionally, the hydrophilic/hydrophobic interactions of the micelles are similar to that in the polar regions of a membrane. Thus, the development of quantitative structure-retention relationships (QRAR) has become widespread. Escuder-Gilabert et al. tested three different QRAR retention models on ionic compounds. Several classes of compounds were tested including catecholamines, local anesthetics, diuretics, and amino acids.
Sources: en.wikipedia.org
It is a synthetic fifteen-amino-acid peptide whose sequence matches part of a protein found in human gastric juice. It is made by chemical synthesis, not purified from tissue. The name derives from an early fragment label, not from a molecular weight.
The sequence corresponds to a segment of a naturally occurring gastric protein, so related sequence material exists in the body. The peptide itself as sold and studied is a laboratory-synthesized product. Whether an identical free peptide circulates naturally is not established.
No major regulatory agency has approved it as a medicine for any indication. It appears in research supply channels and, in some jurisdictions, in compounded preparations. Clinical use therefore sits outside standard approved-product pathways, and regulatory status varies by country.
Reversed-phase liquid chromatography with ultraviolet detection gives a purity estimate, while mass spectrometry confirms molecular mass and flags modifications. Amino acid analysis can add compositional confirmation. Results are most meaningful when a validated reference standard is run alongside the sample.